Study Number:	I20045
Study Gender:	Female
PWG Approval Date:	See web page for date of PWG Approval
Version:	v1.4.3
Stat Version:	v2.9.1A

Study Number: I20045
Test Type: TOX
Route: Oral Gavage
Species/Strain: Mouse/B6C3F1/N

I04G: Mean Body Weight Gain
Test Compound: Phenanthrene
CAS Number: 85-01-8

Date Report Requested: 02/24/2023
Time Report Requested: 09:13:56
Lab: Burleson Research Technologies

Females: SRBC Cohort

Phase	Days	Treatment Groups (mg/kg)											
		0		12.5		25		50		100		200	
		Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N
SD	0 - 6	-0.2 ± 0.2	8	0.0 ± 0.1	7	-0.1 ± 0.2	8	0.4 ± 0.2	8	0.1 ± 0.3	8	-0.3 ± 0.3	8
	6 - 13	0.4 ± 0.2	8	0.7 ± 0.2	6	0.4 ± 0.2	5	0.4 ± 0.2	8	0.7 ± 0.2	6	0.2 ± 0.4	6
	13 - 20	0.8 ± 0.2	8	1.0 ± 0.2	6	0.8 ± 0.1	5	1.4 ± 0.2	8	1.4 ± 0.3	5	1.3 ± 0.3	6
	20 - 28	0.5 ± 0.8 *	8	0.7 ± 0.1	6	0.6 ± 0.2	5	0.2 ± 0.2	8	0.7 ± 0.3	5	0.2 ± 0.2	6
	0 - 28	1.5 ± 0.7	8	2.4 ± 0.2	6	1.5 ± 0.4	5	2.4 ± 0.6	8	3.0 ± 0.6	5	1.5 ± 0.6	6

Study Number: I20045
Test Type: TOX
Route: Oral Gavage
Species/Strain: Mouse/B6C3F1/N

I04G: Mean Body Weight Gain
Test Compound: Phenanthrene
CAS Number: 85-01-8

Date Report Requested: 02/24/2023
Time Report Requested: 09:13:56
Lab: Burleson Research Technologies

Females: SRBC Cohort

Phase	Days	Treatment Groups (mg/kg)			
		400		50 mg/kg CPS	
		Wt Gain (g)	N	Wt Gain (g)	N
SD	0 - 6	0.3 ± 0.2	8	1.1 ± 0.3 **	8
	6 - 13	0.2 ± 0.3	7	0.6 ± 0.3	8
	13 - 20	1.1 ± 0.3	7	1.1 ± 0.3	8
	20 - 28	0.0 ± 0.2	7	-0.9 ± 0.2	8
	0 - 28	1.5 ± 0.2	7	1.9 ± 0.8	8

Study Number: I20045
Test Type: TOX
Route: Oral Gavage
Species/Strain: Mouse/B6C3F1/N

I04G: Mean Body Weight Gain
Test Compound: Phenanthrene
CAS Number: 85-01-8

Date Report Requested: 02/24/2023
Time Report Requested: 09:13:56
Lab: Burleson Research Technologies

Females: Immunopath Cohort

Phase	Days	Treatment Groups (mg/kg)											
		0		12.5		25		50		100		200	
		Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N
SD	0 - 6	0.1 ± 0.3 *	8	-0.4 ± 0.2	8	0.2 ± 0.3	7	0.4 ± 0.2	6	-0.1 ± 0.1	6	0.2 ± 0.4	7
	6 - 13	0.6 ± 0.3	8	0.4 ± 0.1	8	0.2 ± 0.3	6	0.2 ± 0.3	5	0.7 ± 0.4	5	0.4 ± 0.1	7
	13 - 20	1.1 ± 0.5	8	0.8 ± 0.2	8	0.9 ± 0.2	6	0.5 ± 0.2	5	0.8 ± 0.4	5	0.8 ± 0.2	7
	20 - 28	-0.0 ± 0.4	7	0.1 ± 0.2	7	0.3 ± 0.3	6	0.6 ± 0.4	5	0.2 ± 0.1	5	0.1 ± 0.2	6
	0 - 28	1.8 ± 0.6	7	0.9 ± 0.5	7	1.6 ± 0.6	6	1.6 ± 0.4	5	1.7 ± 0.5	5	1.8 ± 0.4	6

Study Number: I20045
Test Type: TOX
Route: Oral Gavage
Species/Strain: Mouse/B6C3F1/N

I04G: Mean Body Weight Gain
Test Compound: Phenanthrene
CAS Number: 85-01-8

Date Report Requested: 02/24/2023
Time Report Requested: 09:13:56
Lab: Burleson Research Technologies

Females: Immunopath Cohort

Phase	Days	Treatment Groups (mg/kg)			
		400		50 mg/kg CPS	
		Wt Gain (g)	N	Wt Gain (g)	N
SD	0 - 6	0.8 ± 0.3	8	0.3 ± 0.5	8
	6 - 13	0.6 ± 0.4	8	0.9 ± 0.5	8
	13 - 20	0.9 ± 0.3	8	1.0 ± 0.4	8
	20 - 28	-0.5 ± 0.1	8	-1.2 ± 0.4	8
	0 - 28	1.8 ± 0.4	8	1.0 ± 0.6	8

LEGEND

Data are displayed as mean ± SEM
SD – Study Day
Statistical analysis of weight data performed by Jonckheere (trend) and Williams or Dunnett (pairwise) tests.
Statistical analysis for the positive control group compared to the vehicle control group was performed using the t-Test.
Statistical significance for the control group indicates a significant trend test
Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group
* Statistically significant at P <= 0.05
** Statistically significant at P <= 0.01
CPS = Cyclophosphamide

** END OF REPORT **